Learn more

SANOFI PASTEUR SA

Overview
  • Total Patents
    132
  • GoodIP Patent Rank
    42,150
  • Filing trend
    0.0%
About

SANOFI PASTEUR SA has a total of 132 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2004. It filed its patents most often in United States, EPO (European Patent Office) and Canada. Its main competitors in its focus markets chemical engineering, pharmaceuticals and biotechnology are SANOFI PASTEUR S A, ANHUI XIANFENG PARMACEUTICAL CO LTD and BEIJING SHOUER PHARMACEUTICAL FACTORY.

Patent filings per year

Chart showing SANOFI PASTEUR SAs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Plitzko Matthias 77
#2 Struschka Manfred 77
#3 Luy Bernhard 76
#4 Gebhard Thomas 52
#5 Kaiser Roland 19
#6 Forrat Remi 13
#7 Lang Jean 12
#8 Bernhard Luy 12
#9 Matthias Plitzko 12
#10 Manfred Struschka 12

Latest patents

Publication Filing date Title
CA2955562A1 Liquid feeding device for the generation of droplets
MX2014004040A Heating device for rotary drum freeze-dryer.
EP2668201A2 Immunological compositions comprising hiv gp41 polypeptide derivatives
EP2578976A1 Rotary drum for use in a vacuum freeze-dryer
EP2578974A1 Process line for the production of freeze-dried particles
EP2578975A1 Rotary drum freeze-dryer
WO2012028315A1 A stabilizer for the preparation of a dry polio injectable vaccine composition
FR2918074A1 Process for purifying a viral suspension
FR2914302A1 PROCESS FOR PREPARING PORPHYRIN DERIVATIVES, SUCH AS PROTOPORPHYRIN (IX) AND INTERMEDIATE SYNTHESIS
FR2906724A1 Method of immunization against the 4 serotypes of dengue.
FR2903605A1 Immunization method against the four serotypes of dengue
FR2899110A1 Immunogenic composition, useful for immunizing against Staphylococcus aureus infection, comprises capsular polysaccharide of type 8 and 5 of Staphylococcus aureus strain overproducing type 8 and/or type 5, respectively
FR2888117A1 Vaccine composition comprising a thermoreversible emulsion
FR2884830A1 Producing an overexpressive strain of Staphylococcus aureus for producing a polysaccharide capsular, comprises culturing the strain on a culture medium and optionally recovering the produced strain from the medium
FR2881050A1 Dcchol in the new-nes